ArticleMolecular psychiatry2021
Longitudinal pathways of cerebrospinal fluid and positron emission tomography biomarkers of amyloid-β positivity.
Article in Molecular psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 38 citations in OpenAlex.
- Redefining Idiopathic Normal Pressure Hydrocephalus Using AI-Driven Brain Volumetry.Biomedicines · 2026Article
- Plasma p-tau217 assays effectively predict amyloid status but lack precision for tau staging in Alzheimer's disease.Journal of neurology · 2026Article
- Eligibility for Anti-Amyloid-β Monoclonal Antibodies in Patients With Primary Progressive Aphasia due to Alzheimer's Disease in Japan.Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society · 2026Article
- Amyloid Probability in Alzheimer Disease From Plasma, Cerebrospinal Fluid, and Amyloid Imaging.Research square · 2026Article
- A Biomarker-Based Classification of Corticobasal Syndrome.Movement disorders : official journal of the Movement Disorder Society · 2026Article
- Plasma phosphorylated tau217 strongly associates with memory deficits in the Alzheimer's disease spectrum.Brain : a journal of neurology · 2025Article
- Diagnostic Challenge in Frontal Variant Alzheimer's Disease With Low Amyloid-β PET Retention.Annals of clinical and translational neurology · 2025Article
- Depressive Symptoms and Amyloid Pathology.JAMA psychiatry · 2025Article
- Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Targeting Soluble Amyloid Oligomers in Alzheimer's Disease: A Hypothetical Model Study Comparing Intrathecal Pseudodelivery of mAbs Against Intravenous Administration.Diseases (Basel, Switzerland) · 2025Article
- Continuous β-Amyloid CSF/PET Imbalance Model to Capture Alzheimer Disease Heterogeneity.Neurology · 2024Article
- Subsequent correlated changes in complement component 3 and amyloid beta oligomers in the blood of patients with Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Machine learning prediction of future amyloid beta positivity in amyloid-negative individuals.Alzheimer's research & therapy · 2024Article
- Characteristics of discordance between amyloid positron emission tomography and plasma amyloid-β 42/40 positivity.Translational psychiatry · 2024Article
- A review of the flortaucipir literature for positron emission tomography imaging of tau neurofibrillary tangles.Brain communications · 2024Review
- Differential associations of clinical features with cerebrospinal fluid biomarkers in dementia with Lewy bodies and Alzheimer's disease.Aging clinical and experimental research · 2023Article
- Advances in Molecular Psychiatry - March 2023: mitochondrial function, stress, neuroinflammation - bipolar disorder, psychosis, and Alzheimer's disease.Molecular psychiatry · 2023Article
- Contribution of clinical information to the predictive performance of plasma β-amyloid levels for amyloid positron emission tomography positivity.Frontiers in aging neuroscience · 2023Article
- Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.JAMA neurology · 2022Article
- β-Amyloid discordance of cerebrospinal fluid and positron emission tomography imaging shows distinct spatial tau patterns.Brain communications · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
Mismatch between CSF and PET amyloid-β biomarkers occurs in up to ≈20% of preclinical/prodromal Alzheimer's disease individuals. Factors underlying mismatching results remain unclear. In this study we hypothesized that CSF/PET discordance provides unique biological/clinical information. To test this hypothesis, we investigated non-demented and demented participants with CSF amyloid-β
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.